Optimer Pharmaceuticals, Inc. (OPTR) said The Lancet Infectious Diseases has published results from the European and North American Phase 3 trial evaluating the safety and efficacy of DIFICID tablets in the treatment of adult patients with Clostridium difficile infection.
The company noted that the Phase 3 Study results confirmed superior rate of sustained clinical response of DIFICID tablets compared to oral vancomycin in adult patients with Clostridium difficile infection. The Phase 3 non-inferiority trial showed that DIFICID had similar clinical cure rates as oral vancomycin in the initial treatment of the disease.
In addition, secondary endpoint analyses showed that DIFICID provided superior rates of sustained clinical response through 25 days after the end of treatment and had significantly lower recurrence rates within four weeks of treatment.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.